Outcome and Prognostic Factors of Low-Grade Astrocytoma: Namazi Hospital, Shiraz, Iran (2006–2013)

Document Type : Original Article


1 Department of Radiation oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Golestan University of Medical Sciences, Gorgan, Iran.

3 Breast Diseases Research Center, school of medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

4 Department of Radiation Oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

5 Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

6 Center for Collaborative Research, Orlando, Florida, USA.


Introduction: Primary brain tumors, although not among the most common site of tumors, are considered an important pathology, due to their high mortality rate. Astrocytoma is a glial brain tumor with a high mortality rate. The predictors of the patients’ outcome is thus of great importance. In the present study, we investigated the results of 7–year follow–up of patients with astrocytoma in order to determine the prognostic factors associated with patients’ survival. Methods: In this cross–sectional study, 115 patients suffering from astrocytoma grade II, who referred to radio–oncology department of Nemazee hospital between 2006 and 2013, were included. The patients’ overall survival (OS) and disease–free survival (DFS) were recorded and their difference according to demographic and clinical characteristics of patients, as well as the treatment used, was evaluated using SPSS v.25.Results: Mean age of patients was 35.34±15.17 years; most were younger than 40 years old (71%) and men (59%). Mean OS and DFS were 74.90±43.05 and 26.61±26.97 months, respectively. Patients younger than 40 had a significantly longer mean OS (84.04±37.93 vs. 53.04±47.41 months; P=0.004). Mean DFS was different according to chemotherapy and dose of radiotherapy (P=0.041 and 0.01, respectively), while OS was not (P>0.05). Conclusion: Considering the difference in outcome of patients, specifically DFS, according to the performance of chemotherapy and the dose of radiotherapy, it is recommended to pay greater attention to appropriate choice of treatment strategy of patients with astrocytoma. Further randomized controlled studies are required to determine the predictors of patients’ outcome.


Main Subjects

Editor: SAA. Safavi-Naini (Conflict of interest: None)
Reviewers: A. Tamimi (Conflict of interest: None), P. Jamshidi (Conflict of Intrest: None)

1.    de Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St. Germaine-Smith C, et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro-oncology. 2015;17(6):776-83.
2.    Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.
3.    Comelli I, Lippi G, Campana V, Servadei F, Cervellin G. Clinical presentation and epidemiology of brain tumors firstly diagnosed in adults in the Emergency Department: a 10-year, single center retrospective study. Annals of translational medicine. 2017;5(13).
4.    Mabray MC, Barajas RF, Cha S. Modern brain tumor imaging. Brain tumor research and treatment. 2015;3(1):8-23.
5.    Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, et al. Assessment of the evolution of cancer treatment therapies. Cancers. 2011;3(3):3279-330.
6.    Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, et al. Challenges to curing primary brain tumours. Nature reviews Clinical oncology. 2019;16(8):509-20.
7.    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica. 2007;114(2):97-109.
8.    Perkins A, Liu G. Primary brain tumors in adults: diagnosis and treatment. American family physician. 2016;93(3):211-7.
9.    Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro-oncology. 2018;20(suppl_4):iv1-iv86.
10.    Walker C, Baborie A, Crooks D, Wilkins S, Jenkinson M. Biology, genetics and imaging of glial cell tumours. The British journal of radiology. 2011;84(special_issue_2):S90-S106.
11.    Barragán-Pérez EJ, Altamirano-Vergara CE, Alvarez-Amado DE, García-Beristain JC, Chico-Ponce-de-León F, González-Carranza V, et al. The Role of Time as a Prognostic Factor in Pediatric Brain Tumors: a Multivariate Survival Analysis. Pathology & Oncology Research. 2020;26(4):2693-701.
12.    Deb S, Pendharkar AV, Schoen MK, Altekruse S, Ratliff J, Desai A. The effect of socioeconomic status on gross total resection, radiation therapy and overall survival in patients with gliomas. Journal of neuro-oncology. 2017;132(3):447-53.
13.    Almenawer SA, Badhiwala JH, Alhazzani W, Greenspoon J, Farrokhyar F, Yarascavitch B, et al. Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro-oncology. 2015;17(6):868-81.
14.    Yang K, Nath S, Koziarz A, Badhiwala JH, Ghayur H, Sourour M, et al. Biopsy versus subtotal versus gross total resection in patients with low-grade glioma: a systematic review and meta-analysis. World neurosurgery. 2018;120:e762-e75.
15.    Wegman-Ostrosky T, Reynoso-Noverón N, Mejía-Pérez SI, Sánchez-Correa TE, Alvarez-Gómez RM, Vidal-Millán S, et al. Clinical prognostic factors in adults with astrocytoma: Historic cohort. Clinical neurology and neurosurgery. 2016;146:116-22.
16.    Youland RS, Brown PD, Giannini C, Parney IF, Uhm JH, Laack NN. Adult Low-grade Glioma 19-year Experience at a Single Institution. American journal of clinical oncology. 2013;36(6):612.
17.    Tove L-L, Hanssøn HA, Stein S, Sverre H. Prognostic value of histological features in diffuse astrocytomas WHO grade II. International journal of clinical and experimental pathology. 2012;5(2):152.
18.    Tunthanathip T, Ratanalert S, Sae-Heng S, Oearsakul T, Sakaruncchai I, Kaewborisutsakul A, et al. Prognostic factors and nomogram predicting survival in diffuse astrocytoma. Journal of neurosciences in rural practice. 2020;11(01):135-43.
19.    Spych M, Gottwald L, Jesień‑Lewandowicz E, Sztajer S, Fijuth J. Response to postoperative radiotherapy as a prognostic factor for patients with low-grade gliomas. Oncology letters. 2012;4(3):455-60.
20.    Kumthekar P, Patel V, Bridge C, Rademaker A, Helenowski I, Mrugala MM, et al. Prognosis of older patients with low-grade glioma: a retrospective study. Integrative cancer science and therapeutics. 2017;4(5).
21.    Kashi ASY, Rakhsha A, Houshyari M. Overall survival in adult patients with low-grade, supratentorial glioma: ten years’ follow up at a single institution. Electronic physician. 2015;7(3):1114.
22.    Mucha-Małecka A, Gliński B, Hetnał M, Jarosz M, Urbański J, Frączek-Błachut B, et al. Long-term follow-up in adult patients with low-grade glioma (WHO II) postoperatively irradiated. Analysis of prognostic factors. Reports of Practical Oncology and Radiotherapy. 2012;17(3):141-5.
23.    Anvari K, Toussi MS, Shahidsales S, Motlagh F, Ehsaee MR, Afshari F. Treatment outcomes and prognostic factors in adult astrocytoma: In North East of Iran. Iranian journal of cancer prevention. 2016;9(4).
24.    Daniels TB, Brown PD, Felten SJ, Wu W, Buckner JC, Arusell RM, et al. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. International Journal of Radiation Oncology* Biology* Physics. 2011;81(1):218-24.
25.    Jakola AS, Unsgård G, Myrmel KS, Kloster R, Torp SH, Losvik OK, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica. 2013;155(12):2227-35.
26.    Kaya V, Aksu MG, Korcum AF, Özdemir B, Çeçen Y, Sindir B, et al. Clinical prognostic factors of adjuvant radiation therapy for low-grade gliomas: results of 10 years survival. International journal of clinical and experimental medicine. 2014;7(5):1336.
27.    Tang S, Liao J, Long Y. Comparative assessment of the efficacy of gross total versus subtotal total resection in patients with glioma: a meta-analysis. International Journal of Surgery. 2019;63:90-7.
28.    Hardesty DA, Sanai N. The value of glioma extent of resection in the modern neurosurgical era. Frontiers in neurology. 2012;3:140.
29.    Dong X, Noorbakhsh A, Hirshman BR, Zhou T, Tang JA, Chang DC, et al. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis. Neuro-oncology practice. 2016;3(1):29-38.